

| First Name:     | Middle<br>Initial:    |
|-----------------|-----------------------|
| Street Address: |                       |
| City:           |                       |
| State:          |                       |
| ZIP Code:       |                       |
|                 |                       |
|                 | Street Address: City: |

| MMR (Measles, Mumps, Rubella) – 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option. |  |                         |                                |                       | Copy<br>Attached |
|---|--|-------------------------|--------------------------------|-----------------------|------------------|
| Option1   | Vaccine  | Date                    |                                |                       |                  |
| MMR<br>-2 doses of MMR  | MMR Dose #1  |                         |                                |                       |                  |
| vaccine   | MMR Dose #2  |                         |                                |                       |                  |
| Option 2  | Vaccine or Test  | Date                    |                                |                       |                  |
| Measles   | Measles Vaccine Dose #1                                |                         | Serology Results               |                       |                  |
| -2 doses of vaccine or  | Measles Vaccine Dose #2                                |                         | Qualitative<br>Titer Results:  | ☐ Positive ☐ Negative |                  |
| positive serology   | Serologic Immunity (IgG, antibodies, titer)            |                         | Quantitative<br>Titer Results: | IU/ml                 |                  |
| <b>M</b>  | Mumps Vaccine Dose #1                                  |                         | Se                             | Serology Results      |                  |
| Mumps -2 doses of vaccine or  | Mumps Vaccine Dose #2                                  |                         | Qualitative<br>Titer Results:  | ☐ Positive ☐ Negative |                  |
| positive serology   | Serologic Immunity (IgG, antibodies, titer)            |                         | Quantitative<br>Titer Results: | IU/mI                 |                  |
|   |  |                         | Serology Results               |                       |                  |
| Rubella -1 dose of vaccine or   | Rubella Vaccine  |                         | Qualitative<br>Titer Results:  | ☐ Positive ☐ Negative |                  |
| positive serology   | Serologic Immunity (IgG, antibodies, titer)            |                         | Quantitative<br>Titer Results: | IU/mI                 |                  |
| Tetanus-diphtheria-per  | tussis – One (1) dose of adult Tdap. If last Tdap is r | more than 10 years old, | provide date                   | e of last Td and Tdap |                  |
|   | Tdap Vaccine (Adacel, Boostrix, etc)                   |                         |                                |                       |                  |
|   | Td Vaccine (if more than 10 years since last Tdap)     |                         |                                |                       |                  |
| Varicella (Chicken Pox)   | -2 doses of vaccine or positive serology               |                         |                                |                       |                  |
|   | Varicella Vaccine #1                                   |                         | S                              | erology Results       |                  |
|   | Varicella Vaccine #2                                   |                         | Qualitative<br>Titer Results:  | ☐ Positive ☐ Negative |                  |
|   |  |                         | Quantitative<br>Titer Results: | IU/ml                 |                  |
| Influenza Vaccine1 dose annually each fall  |  |                         |                                |                       |                  |
| Second flu vaccine is   |  | Date                    |                                |                       |                  |
| for updating your form only   | Flu Vaccine  |                         |                                |                       |                  |
| ·   | Flu Vaccine  |                         |                                |                       |                  |



| Name:   |  |   | Date of B  | Birth:   |          |                  |  |
|---|--|---|--|--|----------|------------------|--|
| (Last, First, Middle Initial) (mm/dd/yyyy)  |  |   |  |  |          |                  |  |
| Hepatitis B Surface Antibody (<br>negative complete the remain<br>Hepatitis B Surface Antibod   | On3 doses of Engergix-B, Recombivax or Twinrix (titer) preferably drawn 4-8 weeks after 3'd dose. If ne ider of the second series followed by another titer draw y is still negative after a secondary series, additional to a secondary series, additional to a secondary series and counseling purposes assignments and counseling purposes. | egative,<br>wn 4-8 v<br>testing ir<br>Documei | give a 4 <sup>th</sup> dose and rep<br>weeks after the last dos<br>ncluding Hepatitis B Su<br>ntation of Chronic Activ | neat a titer in 4-8 weeks.<br>se of the second series.<br>Irface Antigen should be | If<br>If | Copy<br>Attached |  |
|   | 3-dose vaccines (Energix-B, Recombivax, Twinrix) 2-dose vaccines (Heplisav-B)  |   | B Dose Series  | 2 Dose Series  |          |                  |  |
| Primary<br>Hepatitis B Series   | Hepatitis B Vaccine Dose #1  | _   |  | /  |          |                  |  |
| Heplisav-B only requires two  | Hepatitis B Vaccine Dose #2  | _   |  |  |          |                  |  |
| doses of vaccine followed by antibody testing   | Hepatitis B Vaccine Dose #3  | _   |  |  |          |                  |  |
|   | QUANTITATIVE Hep B Surface<br>Antibody   |   | _//_   | IU/ml  |          |                  |  |
| Secondary   |  | 3   | B Dose Series  | 2 Dose Series  |          |                  |  |
| Hepatitis B Series  | Hepatitis B Vaccine Dose #4  | _   | //   | /  |          |                  |  |
| Only If no response to<br>primary series  | Hepatitis B Vaccine Dose #5  | _   | _//  | //   |          |                  |  |
| Heplisav-B only requires two doses of vaccine followed by   | Hepatitis B Vaccine Dose #6  | _   | _//  |  |          |                  |  |
| antibody testing  | QUANTITATIVE Hep B Surface<br>Antibody   | _   | _//  | IU/ml  |          |                  |  |
| Hepatitis B Vaccine<br>Non-responder  | Hepatitis B Surface Antigen  | _   |  | ☐ Positive ☐ Negative  |          |                  |  |
| (If Hepatitis B Surface Antibody Negative after<br>Primary and Secondary Series)  | Hepatitis B Core Antibody  | _   |  | ☐ Positive ☐ Negative  |          |                  |  |
| Chronic Active  | Hepatitis B Surface Antigen  | _   |  | ☐ Positive ☐ Negative  |          |                  |  |
| Hepatitis B   | Hepatitis B Viral Load   | _   | _//  | copies/ml  |          |                  |  |
|   | Additional Docu  | ımenta  | ation  |  |          |                  |  |
| <u>Some institutions</u> may have additional requirements depending upon rotation, school requirements or state law. Examples include meningitis vaccine which is mandated in some states if you live in dormitory style housing. If you will be participating in an international experience you may also be required to provide proof of vaccines such as yellow fever or typhoid. Respiratory Fit Testing, etc |  |   |  |  |          |                  |  |
| Vaccination, Test or Examination  |  |   | Date   | Result or<br>Interpretation  | on       | Copy<br>Attached |  |
| Physical Exam (if required)   |  |   |  |  |          |                  |  |
| Respiratory Fit Testing   |  |   | //   |  |          |                  |  |
|   |  |   | //   |  |          |                  |  |
|   |  |   | //   |  |          |                  |  |
|   |  |   | //   |  |          |                  |  |
|   |  |   | //   |  |          |                  |  |
|   | •  |   | //   |  |          |                  |  |



| Name: Date  |   |   |                      |                   | Date of Birt               | Date of Birth:    |                    |                  |
|---|---|---|----------------------|-------------------|----------------------------|-------------------|--------------------|------------------|
|   | (Last, First, Middle Initial)   |   |                      |                   | (mm/dd/yy                  | yy)               |                    |                  |
|   | TUBERCULOSIS SCREENING - Results of last (2) TSTs (PPDs) or (1) IGS status. If you have a history of a positive TST (PPD)≥10mm or IGRA please treatment below. You only need to complete ONE section.  Skin test or IGRA results should not expire during property or must be updated with the receiving instite. |   |                      |                   | supply informa             | tion regarding an | y evaluation a     | r BCG<br>nd/or   |
|   |   |   | Tuberculo            | osis Screening H  | listory                    |                   |                    |                  |
|   | Section A   |   | Date Placed          | Date Read         | Result                     | Interp            | retation           | Copy<br>Attached |
|   |   | TST #1  |                      |                   | mm                         | n Pos D           | leg <b>□</b> Equiv | Attached         |
| Σ   |   | TST #2  |                      |                   | mm                         | □ Pos □ N         | leg □ Equiv        |                  |
| isto  | Negative Skin or<br>Blood Test  | TST #3  |                      |                   | mm                         | n Pos D N         | leg □ Equiv        |                  |
| l h   | History   | TST #4  |                      |                   | mm                         | Pos 🗆 N           | leg □ Equiv        |                  |
| و   | Last two skin test<br>or IGRAs required   |   |                      | Date              | Result                     |                   |                    |                  |
| section based on your history   | T-spots or QuantiFERON TB Gold blood tests for  | QuantiFERON TB<br>(Interferon Gamma Relea                           |                      |                   | ☐ Negative                 | □ Indetermin      | ate                |                  |
| ed (  | tuberculosis  Use additional rows as needed   | QuantiFERON TB Gold or T-Spot<br>(Interferon Gamma Releasing Assay) |                      |                   | ☐ Negative ☐ Indeterminate |                   |                    |                  |
| bas   | iows as needed  | QuantiFERON TB<br>(Interferon Gamma Relea                           |                      |                   | ☐ Negative                 | □ Indetermin      | ate                |                  |
| <u>io</u>   |   | QuantiFERON TB<br>(Interferon Gamma Relea                           |                      |                   | ☐ Negative                 | □ Indetermin      | ate                |                  |
| Sct   | Section B   |   | Date Placed          | Date Read         | Result                     |                   |                    |                  |
|   |   | Positive TST  |                      |                   | mn                         | n                 |                    |                  |
| TB  | History of  |   |                      | Date              | Result                     |                   |                    |                  |
| one .   | Latent Tuberculosis,  | QuantiFERON TB<br>(Interferon Gamma Relea                           |                      |                   | □ Positive                 | ☐ Negative ☐ Ir   | ndeterminate       |                  |
|   | Positive Skin<br>Test or<br>Positive Blood  | Chest X-ray   |                      |                   |                            |                   |                    |                  |
| lo (  | Test  | Treated for latent T  | B?                   |                   | ☐ Yes ☐ No                 |                   |                    |                  |
| Positive Blood Test Treated for latent TB?    GRAs include T-spots or QuantifERON TB Gold blood tests for tuberculosis   Total Duration of treatment latent |   |   | TB, list medications | taken:            |                            |                   |                    |                  |
| ΙĔ  |   | Total Duration of treatment latent TB?                              |                      |                   | Month                      | ıs                |                    |                  |
| ၂ ပ   | Date of Last Annual TB Symptom Questionnaire  |   |                      |                   |                            |                   |                    |                  |
| 3e  | Section C   |   |                      |                   | Date                       |                   |                    |                  |
| leas  |   | Date of Diagnosis   |                      |                   |                            |                   |                    |                  |
| ٦   | History of Active   | Date of Treatment Completed   |                      |                   |                            |                   |                    |                  |
|   | Tuberculosis  | Date of Last Annual TB Symptom Questionnaire                        |                      | tom Questionnaire |                            |                   |                    |                  |
|   | Dat   |   |                      | Last Chest X-ray  |                            |                   |                    |                  |
|   |   |   |                      |                   |                            |                   |                    |                  |



| me: |                               | Date of Birth: |  |
|-----|-------------------------------|----------------|--|
|     | (Last, First, Middle Initial) | (mm/dd/yyyy)   |  |
|     | Addition                      | al Information |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |
|     |                               |                |  |

### MUST BE COMPLETED BY YOUR HEALTH CARE PROVIDER OR INSTITUTIONAL DESIGNEE:

| Authorized Signature: |         | Date:            |
|-----------------------|---------|------------------|
| Printed Name:         |         | Office Use Only  |
| Title:                |         | Office Ose Offiy |
| Address Line 1:       |         |                  |
| Address Line 2:       |         |                  |
| City:                 |         |                  |
| State:                |         |                  |
| Zip:                  |         |                  |
| Phone:                | () Ext: |                  |
| Fax:                  | ()      |                  |
| Email Contact:        |         |                  |

#### \*Sources

- 1. Hepatitis B In: Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015
- 2. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, Vol 60(7):1-45
- 3. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, MMWR, Vol 62(RR10):1-19
- 4. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Vol 67(1):1-31